Pemetrexed
Links shared publicly online about this topic
Dr. Scagliotti on Personalizing Care With Pemetrexed
onclive.com — “Dr. Giorgio V. Scagliotti from the University of Turin Discusses Personalizing Care With Pemetrexed” View full resource at onclive.com
Most Recently Shared on August 31, 2011 at 8:29 pm By:
Dr. Giorgio V. Scagliotti from the University of Turin Discusses Personalizing Care With Pemetrexed http://t.co/evQg3Zg #OncLiveTV
Dr. West Explains the Pemetrexed Clinical Trial
onclive.com — “Dr. Jack West from Swedish Cancer Institute Explains the Pemetrexed Clinical Trial” View full resource at onclive.com
Most Recently Shared on July 22, 2011 at 9:32 pm By:
@JackWestMD from @Swedish Explains the Pemetrexed Clinical Trial http://t.co/DnIJaor #lungcancer #onclivetv
Dr. Langer Discusses the JMEN Maintenance Pemetrexed Trial
onclive.com — “Dr. Corey J. Langer from Abramson Cancer Center Discusses the JMEN Maintenance Pemetrexed Trial” View full resource at onclive.com
Most Recently Shared on October 6, 2011 at 8:34 pm By:
Dr. Corey J. Langer from @PennMedicine Abramson Cancer Center Discusses the JMEN Maintenance Pemetrexed Trial http://ow.ly/6POaJ #OncLiveTV
NICE Recommends Pemetrexed For The Treatment Of Non-small-cell Lung Cancer
medicalnewstoday.com — “The national institute for health and clinical excellence (nice) has published final guidance on the use of pemetrexed for the treatment of non-small-cell lung cancer (nsclc). the guidance recomme” View full resource at medicalnewstoday.com
Most Recently Shared on September 24, 2009 at 4:34 pm By:
NICE Recommends Pemetrexed For The Treatment Of Non-small-cell Lung Cancer: The National Institute for Health an.. http://bit.ly/Pw0x3
Lung Cancer ALK Rearrangement May Predict Pemetrexed Efficacy, Study Shows
medicalnewstoday.com — “Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed (brand name: Alimta) than patients whose cancer did not show ALK translocation, accord” View full resource at medicalnewstoday.com
Most Recently Shared on September 5, 2011 at 7:05 am By:
Lung Cancer ALK Rearrangement May Predict Pemetrexed Efficacy, Study Shows http://mnt.to/3Zpc #lungcancer
First trial of pemetrexed with radiation and chemo in lung cancer shows promising results
sciencedaily.com — “The first trial of an important new combination therapy of treatment with the chemotherapy drug pemetrexed concurrent with radiation in lung cancer has delivered promising results.” View full resource at sciencedaily.com
Most Recently Shared on April 30, 2010 at 3:35 pm By:
First trial of pemetrexed with radiation and chemo in lung cancer shows promising results: The first trial of an i... http://bit.ly/bd3Xzs
Pemetrexed garners good response in ALK-rearranged lung cancer - ONA
oncologynurseadvisor.com — “Pemetrexed (Alimta) appears to be an effective treatment in persons with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive.” View full resource at oncologynurseadvisor.com
Most Recently Shared on September 21, 2011 at 12:08 pm By:
OncologyNurseAdvisor Nursing, Medical Education, Medical Publisher, and Oncology
Pemetrexed garners good response in ALK-rearranged #lung #cancer http://t.co/n6xoR7RB
Dr Paz-Ares Discusses Pemetrexed Clinical Trial
onclive.com — “Dr Paz-Ares from Seville University Hospital Discusses Pemetrexed Clinical Trial” View full resource at onclive.com
Most Recently Shared on June 13, 2011 at 7:01 pm By:
Dr Paz-Ares Discusses the Pemetrexed Advanced Nonsquamous Non–Small Cell Lung Cancer Clinical Trial http://t.co/78T3nPH
Dr. Paz-Ares Discusses the Use of Pemetrexed for NSCLC
onclive.com — “Dr. Paz-Ares From Seville University Hospital Discusses the Use of Pemetrexed for NSCLC” View full resource at onclive.com
Most Recently Shared on June 17, 2011 at 8:07 pm By:
OncLive TV: Dr. Paz-Ares From Seville University Hospital Discusses the Use of Pemetrexed for NSCLC http://t.co/iOuKd3d
First trial of pemetrexed with radiation and chemo in lung cancer shows promising results
physorg.com — “The first trial of an important new combination therapy of treatment with the chemotherapy drug pemetrexed concurrent with radiation in lung cancer has delivered promising results, French researchers report at the 2nd European Lung Cancer Conference.” View full resource at physorg.com
Most Recently Shared on April 30, 2010 at 1:20 pm By:
PhysOrg Health News Health News
First trial of pemetrexed with radiation and chemo in lung cancer shows promising results http://tw.physorg.com/191834575
Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows
eurekalert.org — “Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed (brand name: Alimta) than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC).” View full resource at eurekalert.org
Most Recently Shared on September 2, 2011 at 7:20 pm By:
Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows: (International Association for the S... http://t.co/u0Iyjbt
Symposier - Dr. Paz-Ares Discusses the Use of Pemetrexed for NSCLC
symposier.com — “Uploaded and shared in Youtube by: OncLiveTV — Luis Paz-Ares, MD, PhD the chair of oncology at Seville University Hospital in Spain discusses the use of pemetrexed in advanced nonsquamous non--small cell lung cancer.” View full resource at symposier.com
Most Recently Shared on June 22, 2011 at 7:11 pm By:
Dr. Paz-Ares Discusses the Use of Pemetrexed for advanced nonsquamous non--small cell lung cancer. http://bit.ly/lBbSYY
Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients
news-medical.net — “Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer.” View full resource at news-medical.net
Most Recently Shared on September 2, 2011 at 1:19 pm By:
News-Medical.Net Oncology and Health News
Oncology News: Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients: Patients with A... http://t.co/iXa3406
Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows
eurekalert.org — “Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed (brand name: Alimta) than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC).” View full resource at eurekalert.org
Most Recently Shared on September 1, 2011 at 7:06 pm By:
Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows: ( International Association for the ... http://t.co/igBmUh1
Medical News: ASCO: Pemetrexed Delays Lung Cancer Progression - in Meeting Coverage, ASCO from MedPage Today
medpagetoday.com — “CHICAGO -- Maintenance therapy with pemetrexed (Alimta) appears to significantly extend progression-free survival in advanced lung cancer patients, although the difference when compared with placebo i” View full resource at medpagetoday.com
Most Recently Shared on June 10, 2011 at 5:42 pm By:
ASCO: Pemetrexed Delays Lung Cancer Progression http://bit.ly/jYdsrc
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Editor
Editors of Oncology & Biotech News/Oncology Net Guide/OncNurse/Contemporary Oncology, on cancer news from pharma, trials, technology, & more.
-
Editor
Editors of Oncology & Biotech News/Oncology Net Guide/OncNurse/Contemporary Oncology, on cancer news from pharma, trials, technology, & more.
-
Editor
Editors of Oncology & Biotech News/Oncology Net Guide/OncNurse/Contemporary Oncology, on cancer news from pharma, trials, technology, & more.
Advertisement
